SPECIALTY PHARMA DRIVING THE EMERGENCE OF ACCESS HUBS FOR PRIVATE PAYERS

Size: px
Start display at page:

Download "SPECIALTY PHARMA DRIVING THE EMERGENCE OF ACCESS HUBS FOR PRIVATE PAYERS"

Transcription

1 SPECIALTY PHARMA DRIVING THE EMERGENCE OF ACCESS HUBS FOR PRIVATE PAYERS

2 SPECIALTY PHARMA DRIVING THE EMERGENCE OF ACCESS HUBS FOR PRIVATE PAYERS The rising cost of drugs, fuelled by the growing specialty drugs segment, is challenging the sustainability of private drug plans and forcing employers and carriers to rethink their benefits programs. Employers, faced with the increasing cost of their drug plan, are looking to their carriers to manage claims costs and are becoming more critical of the value provided by their benefits plans. Carriers, who are having more difficulties passing on the higher cost of drugs to employers, are exploring new ways to contain drug spend. This heightened focus on the cost and effectiveness of drug benefits programs represents a major driver of change in the way carriers will compete in the future, moving from a cost-for-service model to one focused on providing value solutions. This shift will require private payers to offer broader cost containment and member support program in an integrated, comprehensive service offering that Pivot Strategy has coined Access Hubs. THE EVOLVING PRIVATE PAYER DRUG PLAN PARADIGM In Canada, the drug plan is the most important component of private payer benefits programs. Today, specialty drugs account for 2% of claims and represent 26% of the total drug costs. They are expected to reach 50% of the drug bill within 2 years, driven by price, utilization growth and an R&D pipeline dominated by specialty drugs. A growing number of non-specialty treatments targeted at large populations and the many emerging oncology treatments are also contributing to escalating drug budgets. Rising drug plan costs are impacting employers and plan members. Employers are increasingly concerned with the sustainability of their benefits plans and are putting pressure on payers to implement cost containment measures. However, they also want to ensure their employees have access to treatments that promote wellness, increase productivity and reduce absenteeism. For plan members, expensive drugs mean higher co-pays. At the same time, they want the medicines best suited to treat their individual conditions and are increasingly willing to submit to different screening processes to have access to the highcost drugs. Plan members are also more amenable to sharing their data regarding their medical condition, adherence, lifestyle and product choices. Specialty drugs are expected to reach 50% of the drug bill within 2 years, driven by price, utilization and an R&D pipeline dominated by expensive medicines. PRIVATE PAYERS TESTING THE WATERS While access to new drugs has been under scrutiny by public payers for some time, it has been straightforward in the private payer market. Once approved by Health Canada, new medicines were listed on private payer formularies at full price. This was made possible by a business model whereby carriers could transfer drug cost increases directly to employers while providing rapid unfettered access to new drugs and treatments to employees. This unrestricted access stood in contrast to the public side. The pan-canadian Pharmaceutical Alliance (pcpa) has been steadily increasing its clout with manufacturers by negotiating over 100 Product Listing Agreements (PLAs) since its inception in These negotiations have resulted in formulary exclusions and agreements focused on price rebates and caps which have created price deltas in the range of 20% with private formularies. 1

3 To date, cost containment approaches deployed by private payers in Canada have been relatively modest compared with the scope and nature of such initiatives in the US or Europe. Most Canadian carriers offer a number of cost containment measures such as generic substitution, preferred provider networks (PPNs), prior authorizations, and managed drug formularies using tiers and co-pays. These cost containment measures have generally been presented as options for employers and employees who have typically preferred to pay the additional cost rather than limit access to medications. Recently major carriers have implemented prior authorization programs for access to high-cost drugs that includes case management and drug delivery via a PPN. These initiatives, which were well received by employers and plan members, are rapidly becoming the new standard within the industry for access to high-cost drugs. The focus of private payers has not been limited to cost. Programs such as AmerisourceBergen s HealthForward have demonstrated that important benefits can be derived through enhanced health case management. The latter, focused on ensuring optimal drug usage, connects health case managers, patients and their physicians to help identify treatment options and provide ongoing support and monitoring while driving greater efficiency of the drug spend. THE EMERGENCE OF ACCESS HUBS As shown in Figure 1, the measures described above are the initial steps that have generally been embraced by the private payer community in Canada. However, payers are broadening cost containment measures targeting drug acquisition costs and enhancing plan member programs focused on member support. For these measures to be most effective, they need to be more closely aligned than what has been the case to date. This greater integration of a more comprehensive suite of services will, we believe, lead to the emergence of Access Hubs. FIGURE 1 THE EVOLUTION OF THE RESPONSE OF PRIVATE PAYERS TO SPECIALTY DRUGS TESTING THE WATERS Cost containment approaches becoming the norm Generic substitution Prior authorization PPNs Managed formularies Compulsory payer access programs for high cost drugs Case management & patient support Focus on cost, appropriate use and member experience DEVELOPMENT OF PAYER ACCESS HUBS More aggressive cost focus Private formularies aligning to pcpa price transparency and/or private PLAs (price-focused) Delays and/or refusals in private formulary listing Biosimilar substitution Increased focus on plan member support Case management, patient support, compliance and effectiveness monitoring Innovative value-based payment approaches Outcomes-based PLAs with manufacturers Benefit-sharing programs with employers VALUE SOLUTION Focus on overall plan effectiveness Integrated programs Targeted prevention 2

4 Hubs to regulate access are not new. They were pioneered over a decade ago by pharma companies in the US to help patients and providers secure permission and reimbursement for the first-wave of expensive specialty biotech medications. Private payers are well positioned to drive the development of Access Hubs. As shown in Figure 2, these reimbursement hubs will morph into an integrated, extensive set of services, including navigation support, patient assistance programs, case management, logistics services, PPNs and product listing agreements (PLAs). Modeled on US-based PBMs, they would have tremendous clout in negotiating price concessions and dictating patient support requirements with manufacturers. Private payers are targeting drug acquisition cost and enhancing plan member programs to offer a comprehensive, aligned suite of services that will lead to the emergence of Access Hubs. The emergence of Access Hubs will raise a number of questions. One such question is whether carriers will develop Access Hubs in-house or forge collaborations with existing and emerging providers such as distributors, specialty pharmacy providers, adjudicators, manufacturers drug-related service suppliers. Today, major carriers have chosen to outsource case management and PPNs related to specialty drugs. However, given the potential for cost savings and differentiation, carriers may decide to develop those capabilities in-house and to broaden the scope of Access Hubs to cover a greater proportion of the drug portfolio as well as provide their case management services to more plan members. FIGURE 2 PRIVATE PAYER ACCESS HUBS Data Analytics Health Case Management PPNs/Infusion clinics PLAs PRIVATE PAYER ACCESS HUBS Adjudication Distribution Formulary Design A related question is the speed at which private payers in Canada will start acting on the drug acquisition cost. Although to date they have negotiated only a limited number of PLAs, we believe they are poised to more aggressively expand their use. For example, Manulife has introduced its DrugWatch program targeting high-cost drugs, leveraging information made public by the Canadian Agency for Drugs and Technologies (CADTH) to engage in price discussions with pharma companies. Carriers are also looking to align to pcpa to obtain the discounts it has negotiated or use it as a basis for their own negotiations with manufacturers. Further, with the growth of personalized medicine and the promise of new drugs that have the potential to cure certain diseases (e.g. hepatitis C), there is increased interest in rethinking how we pay for medicines, as evidenced by the growing interest in outcomes-based PLAs. (See related article: Rethinking the way drugs are paid: The opportunity for pharma ). 3

5 CONCLUSION The rising cost of drugs is driving major changes in the private payer market and forcing all players to rethink their business approach and this is only the beginning given the projected increase in the number of new drugs and targeted therapies. For carriers, this signals a change in how they will need to compete in the future. Today, they compete on the breadth of their offer, services to plan members and administrative cost. With the rising cost of drugs, the focus of competition is changing, with greater emphasis on the management of drug cost and eventually that of workforce health and productivity, as seen in the US and Europe. Carriers, who today are focused on choice, service and administrative cost, will need to adopt a strategy based on access, patient support and control of claims cost. The rising cost of drugs is forcing carriers to rethink their business model. Increasingly, they will need to adopt a strategy based on access, patient support and control of claims cost. This pivot in strategy represents a major change in mindset for most carriers today. The development of Access Hubs will be a necessary step towards what we believe is the future of managing specialty drug costs, namely one that is focused on value solutions that cost-effectively deliver on workforce health, productivity and lower absenteeism. CONTACTS For further information on how Pivot Strategy can help develop innovative growth strategies contact: Michel Bernier PhD Managing Partner michel.bernier@pivotstrategy.com Kathy Megyery MA, MBA Partner kathy.megyery@pivotstrategy.com ABOUT PIVOT STRATEGY Pivot Strategy is a strategy boutique specializing in the financial services and healthcare sectors. Pivot s articles explore the impact of important disruptions in the Payer and Pharma sectors. We offer insights regarding early warnings in the industry that may be signaling disruptions on the horizon. Our goal is to help executives focus on the most critical issues and how their organization can seize the opportunities that change presents. 4

Standing strong for payers and patients

Standing strong for payers and patients Standing strong for payers and patients Eric Slusser, EVP, Chief Financial Officer Everett Neville, SVP Supply Chain and Specialty B A N K O F A M E R I C A M E R R I L L L Y N C H H E A LTH C A RE CONFERENCE

More information

Introducing. Manulife DrugWatch. Applying rigorous oversight to help ensure value for money in a dramatically changing drug market

Introducing. Manulife DrugWatch. Applying rigorous oversight to help ensure value for money in a dramatically changing drug market Introducing Manulife DrugWatch Applying rigorous oversight to help ensure value for money in a dramatically changing drug market The drug market in Canada is changing rapidly and dramatically Many Canadians

More information

The Road to Market Access

The Road to Market Access The Road to Market Access From Concept to End of Lifecycle April 2017 CAHR MA 101 ROUBAIX STRATEGIES INC. Roubaix [ru-bae]: The Paris-Roubaix is one of the most difficult single-day professional cycling

More information

TELUS Talks Health. The drug pipeline paradigm shift Game-changing therapies: who pays? The new therapeutic paradigm. March 2016 Edition

TELUS Talks Health. The drug pipeline paradigm shift Game-changing therapies: who pays? The new therapeutic paradigm. March 2016 Edition TELUS Talks Health The drug pipeline paradigm shift Game-changing therapies: who pays? March 2016 Edition Author, Luc Vilandré, Vice-President and General Manager, Health Benefits and Payment Solutions

More information

Standing strong for payers and patients

Standing strong for payers and patients Standing strong for payers and patients Dr. Steve Miller, SVP, Chief Medical Officer Ben Bier, VP Investor Relations W I L L I A M B L A I R 3 7 TH ANNUAL G ROWTH STOCK C ONFERENCE 6.14.17 1 Safe harbor

More information

Managing Specialty Pharmaceuticals: Balancing Access and Affordability

Managing Specialty Pharmaceuticals: Balancing Access and Affordability Managing Specialty Pharmaceuticals: Balancing Access and Affordability Commercial Health Plan Perspective The Health Industry Forum July 16, 2008 Presented by: Margaret M. (Peggy) Johnson, R.Ph. Vice President

More information

The Cost of Specialty Drugs: Payer Perspectives

The Cost of Specialty Drugs: Payer Perspectives ADVISORY REPORT AM PL E PA G ES S A S G ES A FirstWord Dossier Advisory report Published Copyright 2016 Doctor s Guide Publishing Limited Part of the FirstWord Dossier family of reports exploring important

More information

Inside: Critical information about your company s prescription drug benefit.

Inside: Critical information about your company s prescription drug benefit. Inside: Critical information about your company s prescription drug benefit. Questions Company Benefits Managers Must Ask Their PBM It pays to make an informed decision harmacy Benefit Managers, often

More information

WorldatWork You and Your PBM: Improving Discounts, Fees and Rebates, and Beyond. Kristin Begley, Pharm.D. Principal

WorldatWork You and Your PBM: Improving Discounts, Fees and Rebates, and Beyond. Kristin Begley, Pharm.D. Principal WorldatWork You and Your PBM: Improving Discounts, Fees and Rebates, and Beyond Kristin Begley, Pharm.D. Principal Presentation Overview The future of drug trend Prescription drug management levers: Contracting

More information

Insurance & Medication Access

Insurance & Medication Access Insurance & Medication Access Ontario Rheumatology Association 12th Annual Meeting JW Marriott The Rosseau Muskoka May 25, 2013 Suzanne Lepage, Private Health Plan Strategist Learning Objectives Understand

More information

It takes a village. Sustainable drug plans that reduce spend; not access

It takes a village. Sustainable drug plans that reduce spend; not access TELUS Talks Health April 2017 Edition It takes a village. Sustainable drug plans that reduce spend; not access Luc Vilandré, Vice President and Chief Operating Officer Karen Kesteris, Director of Payor

More information

Lindsey Imada, PharmD Candidate 2016 Midwestern University, Chicago College of Pharmacy

Lindsey Imada, PharmD Candidate 2016 Midwestern University, Chicago College of Pharmacy Lindsey Imada, PharmD Candidate 2016 Midwestern University, Chicago College of Pharmacy Under the Preceptorship of Dr. Craig Stern Pro Pharma Pharmaceutical Consultants, Inc. September 11, 2015 S OBJECTIVES

More information

250 Dundas Street West, Suite 500 Toronto ON, M5T 2Z5 (Contact)

250 Dundas Street West, Suite 500 Toronto ON, M5T 2Z5 (Contact) Feedback submitted to the Patented Medicines Pricing Review Board from the Multiple Sclerosis Society of Canada related to Excessive Drug Pricing in Canada Deadline: Monday, October 24, 2016 Submitted

More information

PhRMA Perspective: Government Policies to Support Innovative Contracting Approaches

PhRMA Perspective: Government Policies to Support Innovative Contracting Approaches PhRMA Perspective: Government Policies to Support Innovative Contracting Approaches CBI s PAP 2017 Michelle Drozd, Deputy Vice President Policy & Research Department October 12, 2016 Agenda Recent trends

More information

Perspectives Fall Report: 2015 Plan Sponsor Survey

Perspectives Fall Report: 2015 Plan Sponsor Survey Perspectives Fall 2016 Report: Plan Sponsor Survey 2 The Plan Sponsor Survey Report The plan sponsor survey is our eleventh annual survey of 100 plan sponsors with 500 or more members. Larger plan sponsors

More information

How the Federal Government Can Help States Address Rising Prescription Drug Costs

How the Federal Government Can Help States Address Rising Prescription Drug Costs A PUBLICATION OF THE NATIONAL ACADEMY FOR STATE HEALTH POLICY February 2018 How the Federal Government Can Help States Address Rising Prescription Drug Costs Supported by The Commonwealth Fund Introduction

More information

The Declining Value of Payer Access: Defining and improving Rebate Efficiency in the current healthcare landscape

The Declining Value of Payer Access: Defining and improving Rebate Efficiency in the current healthcare landscape The Declining Value of Payer Access: Defining and improving Rebate Efficiency in the current healthcare landscape Lucas Greenwalt, Senior Principal Amundsen Consulting Prepared for: CBI Gross to Net Boot

More information

The Management of Specialty Drugs: Opportunities and Challenges

The Management of Specialty Drugs: Opportunities and Challenges The Management of Specialty Drugs: Opportunities and Challenges Scott Woods Senior Director, Policy PCMA Innovations X April 5, 2016 Specialty Drugs to be Half of Spend by 2018 Forecast PMPM Net Drug

More information

The Funding Landscape for Small Biopharma Ventures,

The Funding Landscape for Small Biopharma Ventures, HEALTHCARE The Funding Landscape for Small Biopharma Ventures, 2010-2015 Trends, strategies and priorities By Gaurav Misra Gaurav Misra Gaurav Misra specializes in pharmaceutical licensing, valuations

More information

CWAG Prescription Drug Pricing Webinar

CWAG Prescription Drug Pricing Webinar CWAG Prescription Drug Pricing Webinar January 9, 2018 Kipp Snider, J.D. Vice President, State Policy Pharmaceutical Research & Manufacturers of America (PhRMA) Medicines Are Expected to Account for a

More information

Disease Management and the Medicare Drug Benefit: Opportunities and Threats for the Pharmaceutical Industry

Disease Management and the Medicare Drug Benefit: Opportunities and Threats for the Pharmaceutical Industry Disease Management and the Medicare Drug Benefit: Opportunities and Threats for the Pharmaceutical Industry Jeffrey A. Bourret, M.S., R.Ph., FASHP Senior Director, Managed Markets Healthcare Systems Marketing

More information

KEEPING PRESCRIPTION DRUGS AFFORDABLE: The Value of Pharmacy Benefit Managers (PBMs)

KEEPING PRESCRIPTION DRUGS AFFORDABLE: The Value of Pharmacy Benefit Managers (PBMs) The Texas Association of Health Plans Representing health insurers, health maintenance organizations, and other related health care entities operating in Texas. KEEPING PRESCRIPTION DRUGS AFFORDABLE: The

More information

Update. The authors of this article are all consultants with Huron Consulting Group, which serves the continuum of life sciences organizations

Update. The authors of this article are all consultants with Huron Consulting Group, which serves the continuum of life sciences organizations Life Science Compliance Update REPRINTED FROM U.S. EDITION Volume 2.1 February 2016 Your Special Relationships Specialty Pharmacies and 5 Thoughtful Controls to Consider public advocates, and the media

More information

Innovative Strategies for Managing the Rising Cost of Specialty Drugs

Innovative Strategies for Managing the Rising Cost of Specialty Drugs Innovative Strategies for Managing the Rising Cost of Specialty Drugs Mid-sized Retirement and Healthcare Plan Management Conference Chicago, IL June 5, 2013 Managing the Rising Cost of Specialty Drugs

More information

INTERNATIONAL TRENDS SERIES

INTERNATIONAL TRENDS SERIES INTERNATIONAL TRENDS SERIES Issue 5: Private Payer Exclusivity Agreements June 8, 2015 Copyright 2015 by PDCI Market Access Inc. The information presented is property of PDCI Market Access. Unauthorized

More information

A VISIBLY DIFFERENT APPROACH TO PHARMACY BENEFITS FOR GOVERNMENT

A VISIBLY DIFFERENT APPROACH TO PHARMACY BENEFITS FOR GOVERNMENT A VISIBLY DIFFERENT APPROACH TO PHARMACY BENEFITS FOR GOVERNMENT AN INNOVATIVE IDEA THAT CHANGED THE INDUSTRY In 2001, frustrated by the limitations and lack of transparency in the traditional pharmacy

More information

Q Formulary Performance:

Q Formulary Performance: Insights Executive Briefing Issue 10, 2016 Q1 2016 Performance: Key Data to Consider as You Look Ahead to 2017 Increasingly our clients see proactive, dynamic formulary management as a necessary response

More information

PERFORMANCE AND TRAJECTORY

PERFORMANCE AND TRAJECTORY PERFORMANCE AND TRAJECTORY José (Joe) E. Almeida Chairman, President and CEO May 21, 2018 Safe Harbor Statement This presentation includes forward-looking statements concerning Baxter s financial results,

More information

Market Access Strategy and Planning: Succeeding in the Age of Value-based Reimbursement

Market Access Strategy and Planning: Succeeding in the Age of Value-based Reimbursement Market Access Strategy and Planning: Succeeding in the Age of -based Reimbursement Presented by: Michael J. Lacey, Senior Director, Strategic Consulting (Life Sciences) Date: March 01, 2017 Truven Health

More information

Avalere Health 2015 Industry Outlook

Avalere Health 2015 Industry Outlook 2015 Industry Outlook 2 Introduction Industry Outlook 2015 Changes in healthcare financing, delivery, and organization are transforming the sector. Health plans and providers are revising their business

More information

Increasing the Value of your Group Benefits Plan and Administration

Increasing the Value of your Group Benefits Plan and Administration Increasing the Value of your Group Benefits Plan and Administration Presented by: Laura Mensch, VP Insurance Solutions Mary Anderson, Product Manager Canadian Employers face constant challenges that make

More information

THIRD-PARTY PHARMACY RECONCILIATION

THIRD-PARTY PHARMACY RECONCILIATION THIRD-PARTY PHARMACY RECONCILIATION Billy Caster Sales Solution Expert Inmar Healthcare Network Jon Brumbaugh Sr. Manager, Product Inmar Healthcare Network Session Description A discussion and presentation

More information

IT TAKES THREE TO TANGO

IT TAKES THREE TO TANGO IT TAKES THREE TO TANGO Structural Collaboration Between Carriers, Providers and Consumers A HEALTHSCAPE ADVISORS EXECUTIVE BRIEFING This HealthScape Advisors Executive Brief discusses a more comprehensive

More information

ECONOMIC PRINCIPLES IMPACTING MANAGED CARE PHARMACY. Adrian Washington PharmD., MBA Vice President of Client Management United Healthcare OptumRx

ECONOMIC PRINCIPLES IMPACTING MANAGED CARE PHARMACY. Adrian Washington PharmD., MBA Vice President of Client Management United Healthcare OptumRx ECONOMIC PRINCIPLES IMPACTING MANAGED CARE PHARMACY Adrian Washington PharmD., MBA Vice President of Client Management United Healthcare OptumRx As vice president, Adrian is responsible for strategic planning

More information

INVESTOR PRESENTATION

INVESTOR PRESENTATION INVESTOR PRESENTATION HURN I Q3 2016 2016 HURON CONSULTING GROUP INC. FORWARD-LOOKING STATEMENTS Statements in this press release that are not historical in nature, including those concerning the Company

More information

Session 88 PD, Drug Claim Management. Presenters: Daniel Berty Suzanne Lepage. SOA Antitrust Disclaimer SOA Presentation Disclaimer

Session 88 PD, Drug Claim Management. Presenters: Daniel Berty Suzanne Lepage. SOA Antitrust Disclaimer SOA Presentation Disclaimer Session 88 PD, Drug Claim Management Presenters: Daniel Berty Suzanne Lepage SOA Antitrust Disclaimer SOA Presentation Disclaimer Industry pooling solution Outcomes and opportunities Dan Berty, Executive

More information

CBI 4th Reimbursement and Contracting Conference: Key Challenges Related to Specialty Drug Pricing and Contracting

CBI 4th Reimbursement and Contracting Conference: Key Challenges Related to Specialty Drug Pricing and Contracting CBI 4th Reimbursement and Contracting Conference: Key Challenges Related to Specialty Drug Pricing and Contracting Avalere Health An Inovalon Company February 28, 2017 Growth in Drug Costs Relative to

More information

Pharmaceutical Market Trends

Pharmaceutical Market Trends Pharmaceutical Market Trends External research and findings Alex Jung 2017 Alex Jung Partner/Managing Director Direct: 312-879-2778 Mobile: 847-722-3482 Email: Alex.Jung@ey.com Office: 155 N Wacker Drive,

More information

The Real-Time Benefit Check Key to Closing the Gaps in Eligibility Driven Formulary. Tony Schueth Chief Executive Officer & Managing Partner

The Real-Time Benefit Check Key to Closing the Gaps in Eligibility Driven Formulary. Tony Schueth Chief Executive Officer & Managing Partner The Real-Time Benefit Check Key to Closing the Gaps in Eligibility Driven Formulary Tony Schueth Chief Executive Officer & Managing Partner Eligibility-Informed Formulary Information Flow Current Workflow

More information

Capturing the Opportunity

Capturing the Opportunity Capturing the Opportunity JANUARY 2018 BETHANY DIPLOMAT PATIENT Copyright 2018 by Diplomat Pharmacy Inc. Diplomat is a registered trademark of Diplomat Pharmacy Inc. All rights reserved. 1 SPECIALTY DRUGS

More information

Insightsfeature. Managing Specialty Drug Spend Under the Medical Benefit. Innovations and Automation for More Effective Management.

Insightsfeature. Managing Specialty Drug Spend Under the Medical Benefit. Innovations and Automation for More Effective Management. Insightsfeature Managing Specialty Drug Spend Under the Medical Benefit Innovations and Automation for More Effective Management March 30, 2017 The Less-Visible Part of Specialty Spend By most estimates,

More information

What to Expect for Pharmacy Benefits and Drug Cost Trends for 2018 & 2019

What to Expect for Pharmacy Benefits and Drug Cost Trends for 2018 & 2019 What to Expect for Pharmacy Benefits and Drug Cost Trends for 2018 & 2019 Mid-Sized Retirement and Healthcare Plan Management Conference 2018. Innovative Rx Strategies, LLC. All rights reserved. The Ever

More information

A VISIBLY DIFFERENT APPROACH TO PHARMACY BENEFITS FOR EMPLOYERS

A VISIBLY DIFFERENT APPROACH TO PHARMACY BENEFITS FOR EMPLOYERS A VISIBLY DIFFERENT APPROACH TO PHARMACY BENEFITS FOR EMPLOYERS AN INNOVATIVE IDEA THAT CHANGED THE INDUSTRY In 2001, frustrated by the limitations and lack of transparency in the traditional pharmacy

More information

MemberChoice FORMULARY MANAGEMENT MEDICATION THERAPY MANAGEMENT (MTM) SPECIALTY DRUG MANAGEMENT. Specialty Drug Management

MemberChoice FORMULARY MANAGEMENT MEDICATION THERAPY MANAGEMENT (MTM) SPECIALTY DRUG MANAGEMENT. Specialty Drug Management MemberChoice FORMULARY MANAGEMENT MEDICATION THERAPY MANAGEMENT (MTM) SPECIALTY DRUG MANAGEMENT SPECIALTY DRUG MANAGEMENT 1 1% Prescriptions Written in 2012 99% 25% Prescription Drug Spending in 2012 75%

More information

The U.S. Healthcare System: How Pharmacy Benefit Managers Impact Prescription Drug Use. Presented by Daniel Tomaszewski Pharmd, PhD

The U.S. Healthcare System: How Pharmacy Benefit Managers Impact Prescription Drug Use. Presented by Daniel Tomaszewski Pharmd, PhD The U.S. Healthcare System: How Pharmacy Benefit Managers Impact Prescription Drug Use Presented by Daniel Tomaszewski Pharmd, PhD 1 Medical Vs. Pharmacy Coverage Medical Insurance Managed by an Insurance

More information

Pharmacy Benefit Managers Overview

Pharmacy Benefit Managers Overview Pharmacy Benefit Managers Overview A Presentation to the House Health Innovation Subcommittee Mary Alice Nye, Ph.D. Health and Human Services Staff Director, OPPAGA December 6, 2017 Pharmacy Benefit Managers

More information

FEEL BETTER. CONNECTED.

FEEL BETTER. CONNECTED. FEEL BETTER. CONNECTED. Connected across pharmacy and medical. To take you further. Katy Wong, RPh, MBA Vice President, Producer Relations Cigna Pharmacy Management Offered by: Cigna Health and Life Insurance

More information

Introduction to the US Health Care System. What the Business Development Professional Should Know

Introduction to the US Health Care System. What the Business Development Professional Should Know Introduction to the US Health Care System What the Business Development Professional Should Know November 2006 1 Understanding of the US Health Care System Evolution of the US health care system to its

More information

Testimony of Mark Merritt. Pharmaceutical Care Management Association

Testimony of Mark Merritt. Pharmaceutical Care Management Association Testimony of Mark Merritt Pharmaceutical Care Management Association Before the UNITED STATES SENATE COMMITTEE ON HEALTH, EDUCATION, LABOR, AND PENSIONS The Cost of Prescription Drugs: How the Drug Delivery

More information

The Canadian Pharmacists Association Response to Proposed Regulation Changes under the Drug Interchangeability and Dispensing Fee Act (DIDFA)

The Canadian Pharmacists Association Response to Proposed Regulation Changes under the Drug Interchangeability and Dispensing Fee Act (DIDFA) Helen Stevenson Executive Officer of Ontario Public Drug Programs and Assistant Deputy Minister Ministry of Health and Long-Term Care 80 Grosvenor Street, 9 th Floor Hepburn Block, Queen s Park Toronto,

More information

PHARMACY BENEFIT MANAGER (PBM)

PHARMACY BENEFIT MANAGER (PBM) PHARMACY BENEFIT MANAGER (PBM) Presentation by: Pantea Ghasemi, USC Pharm.D. Candidate of 2015 Mentor: Dr. Craig Stern, Pro Pharma Consultants Inc. April 3, 2015 OBJECTIVES 1. Define PBM 2. Discuss Service

More information

inventiv Health Supplemental Investor Presentation

inventiv Health Supplemental Investor Presentation inventiv Health Supplemental Investor Presentation May 10, 2017 Disclaimers Non-GAAP Financial Measures This presentation contains the non-gaap financial measures EBITDA and Adjusted EBITDA. EBITDA and

More information

US Reimbursement Systems: Effects on R&D

US Reimbursement Systems: Effects on R&D US Reimbursement Systems: Effects on R&D Patricia M. Danzon, PhD Professor Emeritus The Wharton School University of Pennsylvania Theory: Optimal Reimbursement Rules to Create Efficient R&D Incentives

More information

Drug Pooling Option For Plan Affordability

Drug Pooling Option For Plan Affordability Drug Pooling Option For Plan Affordability A Special Industry Event held by: MONITOR Drug Pooling Option For Plan Affordability was about 1.3 per cent; considerably larger than expected. Created as a not-for-profit

More information

Insights into pharmacy benefit management, drug trend and the future

Insights into pharmacy benefit management, drug trend and the future Insights into pharmacy benefit management, drug trend and the future 1 Where does your health care dollar go? 2 Pharmacy share of total health spend 25% 21% 20% 19% 15% 10% 10% 5% 0% Retail Drugs as a

More information

The 2014 TELUS Health Plan Sponsor Survey

The 2014 TELUS Health Plan Sponsor Survey The 2014 TELUS Health Plan Sponsor Survey Any organization that offers benefits to employees needs to know how the design of their health plan affects costs and employee productivity. A thoughtfully designed

More information

Capturing the Opportunity

Capturing the Opportunity Capturing the Opportunity NOVEMBER 2017 BETHANY DIPLOMAT PATIENT Copyright 2017 by Diplomat Pharmacy Inc. Diplomat is a registered trademark of Diplomat Pharmacy Inc. All rights reserved. 1 DISCLAIMERS

More information

Challenges in High Dollar Drugs. Suzanne Francart, PharmD, BCPS Manager Infusion Services & Medication Assistance Program UNC HealthCare

Challenges in High Dollar Drugs. Suzanne Francart, PharmD, BCPS Manager Infusion Services & Medication Assistance Program UNC HealthCare Challenges in High Dollar Drugs Suzanne Francart, PharmD, BCPS Manager Infusion Services & Medication Assistance Program UNC HealthCare Disclosure I have no relevant conflicts of interest to disclose Learning

More information

Trends disrupting pharmacy value pools and potential implications for the value chain

Trends disrupting pharmacy value pools and potential implications for the value chain Healthcare Systems and Services Practice Trends disrupting pharmacy value pools and potential implications for the value chain Alex Sozdatelev, Suhail Acharya, Megan Colwell, and Shubham Singhal 1 Trends

More information

Pharmacy Program Management: Pitfalls, Challenges, and Best Practices About Solid Benefit Guidance specialty 60,000,000 covered member lives INSIDER

Pharmacy Program Management: Pitfalls, Challenges, and Best Practices About Solid Benefit Guidance specialty 60,000,000 covered member lives INSIDER Pharmacy Program Management: Pitfalls, Challenges, and Best Practices October 2, 2017 This presentation contains proprietary information and is not to be reproduced or further distributed without permission

More information

William Blair 35 th Annual Growth Stock Conference. June 9, 2015 NYSE: Q. Copyright 2014 Quintiles

William Blair 35 th Annual Growth Stock Conference. June 9, 2015 NYSE: Q. Copyright 2014 Quintiles William Blair 35 th Annual Growth Stock Conference June 9, 2015 Copyright 2014 Quintiles NYSE: Q Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking

More information

Meeting the Health Care Challenges of Tomorrow. Jon Roberts Executive Vice President & President, CVS Caremark

Meeting the Health Care Challenges of Tomorrow. Jon Roberts Executive Vice President & President, CVS Caremark Meeting the Health Care Challenges of Tomorrow Jon Roberts Executive Vice President & President, CVS Caremark Agenda PBMs: Needed Now More Than Ever Performance Highlights How We Address Payors #1 Priority:

More information

How ACO s Can Impact Contracting A Real World Example. Mike Medel Pharm D, MBA Banner Health

How ACO s Can Impact Contracting A Real World Example. Mike Medel Pharm D, MBA Banner Health How ACO s Can Impact Contracting A Real World Example Mike Medel Pharm D, MBA Banner Health Agenda Banner Pharmacy Services Introduction Accountable Care Organization Summary Basic Constructs of ACO Partnership

More information

Delivering value in the New Health Economy

Delivering value in the New Health Economy www.pwc.com Delivering value in the New Health Economy New York Health Plan Association November 16, 2017 Healthcare is undergoing a transformation from a closed and highly-siloed industry into a plug-and-play

More information

Estimate of Medicare Part D Costs After Accounting for Manufacturer Rebates

Estimate of Medicare Part D Costs After Accounting for Manufacturer Rebates October 2016 Estimate of Medicare Part D Costs After Accounting for Manufacturer Rebates A Study of Original Branded Products in the U.S. $ Introduction The cost of medicines in the U.S. has been the subject

More information

The Value of Pharmacy Benefit Management And the National Cost Impact of Proposed PBM Legislation. Pharmaceutical Care Management Association

The Value of Pharmacy Benefit Management And the National Cost Impact of Proposed PBM Legislation. Pharmaceutical Care Management Association The Value of Pharmacy Benefit Management And the National Cost Impact of Proposed PBM Legislation Prepared for Pharmaceutical Care Management Association July 2004 Table of Contents I. Introduction and

More information

Pharmacy Benefit Management in Oncology

Pharmacy Benefit Management in Oncology Pharmacy Benefit Management in Oncology October 28 th, 2015 Business Health Care Group Protecting the Future of Oncology Care: A Community Conversation Brent Eberle RPh MBA Chief Pharmacy Officer, Navitus

More information

CUTTING THROUGH THE NOISE

CUTTING THROUGH THE NOISE CUTTING THROUGH THE NOISE WHERE HEALTH PLANS CAN THRIVE IN UNCERTAIN TIMES By Mike Duffy, Nate Holobinko, and Sanjay Saxena, MD Since the passage of the US Affordable Care Act (ACA) in 21, analysts have

More information

Combination Creates Leading Innovator in the Musculoskeletal Industry April 24, 2014

Combination Creates Leading Innovator in the Musculoskeletal Industry April 24, 2014 Combination Creates Leading Innovator in the Musculoskeletal Industry April 24, 2014 David Dvorak President and Chief Executive Officer Jim Crines EVP, Finance, and Chief Financial Officer Cautionary Statement

More information

April 8, Dear Mr. Levinson,

April 8, Dear Mr. Levinson, April 8, 2019 Daniel Levinson Office of Inspector General Department for Health and Human Services Cohen Building, Room 5527 330 Independence Ave, SW Washington, DC 20201 Re: Fraud and Abuse; Removal of

More information

President s Office Bureau du Président

President s Office Bureau du Président President s Office Bureau du Président September 28, 2018 Advisory Council on the Implementation of National Pharmacare Secretariat Brooke Claxton Building 70 Colombine Driveway Ottawa, ON K1A 0K9 Email:

More information

Chasing Opportunity at the County Level: The New Growth Area for China s Pharmaceutical Market

Chasing Opportunity at the County Level: The New Growth Area for China s Pharmaceutical Market www.pwccn.com Chasing Opportunity at the County Level: The New Growth Area for China s Pharmaceutical Market December 2015 The promising county level pharmaceutical market As the world s fastest-growing

More information

Dynamic Therapeutic Formulary (DTF) A Tiered Drug Plan

Dynamic Therapeutic Formulary (DTF) A Tiered Drug Plan Dynamic Therapeutic Formulary (DTF) A Tiered Drug Plan Our tiered DTF drug plan is designed to help you manage drug costs while preserving plan member choice. a two-tiered drug plan. With this approach,

More information

Pharmaceuticals: Can or Should We Do Anything About Rising Drug Costs? Caroline F. Pearson

Pharmaceuticals: Can or Should We Do Anything About Rising Drug Costs? Caroline F. Pearson Pharmaceuticals: Can or Should We Do Anything About Rising Drug Costs? Caroline F. Pearson Avalere Health An Inovalon Company April 2015 Number of News Articles Public Focus on Drug Prices Increased Dramatically

More information

PAY-FOR-PERFORMANCE: THE PROMISE AND CHALLENGES OF OUTCOMES-BASED PHARMACEUTICAL CONTRACTING

PAY-FOR-PERFORMANCE: THE PROMISE AND CHALLENGES OF OUTCOMES-BASED PHARMACEUTICAL CONTRACTING PAY-FOR-PERFORMANCE: THE PROMISE AND CHALLENGES OF OUTCOMES-BASED PHARMACEUTICAL CONTRACTING Sam Peasah PhD, MBA RPh. GA-AMCP-CCORE Winter Symposium March 3, 2018 Samuel Peasah, PhD, MBA, RPh Dr. Peasah

More information

The Role of the Private Sector in Expanding Health Access to the Base of the Pyramid

The Role of the Private Sector in Expanding Health Access to the Base of the Pyramid The Role of the Private Sector in Expanding Health Access to the Base of the Pyramid ABOUT IFC IFC, a member of the World Bank Group, is the largest global development institution focused exclusively on

More information

TouchScript Medication Management System. Financial Impact Analysis on Pharmacy Risk Pools

TouchScript Medication Management System. Financial Impact Analysis on Pharmacy Risk Pools TouchScript Medication Management System Financial Impact Analysis on Pharmacy Risk Pools October 2000 Table of Contents Introduction 3 Executive Summary.. 4-5 Quantitative Analysis 6-10 TouchScript Impact

More information

Magellan Health. Cantor Fitzgerald Healthcare Conference September 26, 2017

Magellan Health. Cantor Fitzgerald Healthcare Conference September 26, 2017 Magellan Health Cantor Fitzgerald Healthcare Conference September 26, 2017 Cautionary Statement and Non-GAAP measures 2 This slide presentation and our accompanying oral comments include forward-looking

More information

MACRAnomics. Patient-Level Economics and Strategic Implications for Providers. Presented to: NW Ohio HFMA October 20, 2016

MACRAnomics. Patient-Level Economics and Strategic Implications for Providers. Presented to: NW Ohio HFMA October 20, 2016 MACRAnomics Patient-Level Economics and Strategic Implications for Providers Presented to: NW Ohio HFMA October 20, 2016 Property of HealthScape Advisors Strictly Confidential 2 MACRAnomics: Objectives

More information

AMERISOURCEBERGEN CORPORATION

AMERISOURCEBERGEN CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September

More information

McKesson Corporation J.P. Morgan Healthcare Conference

McKesson Corporation J.P. Morgan Healthcare Conference McKesson Corporation J.P. Morgan Healthcare Conference John Hammergren Chairman and Chief Executive Officer Forward-Looking Statements Some of the information in this presentation is not historical in

More information

Pharmacy Benefit Strategies for Lowering Prescription Drug Costs

Pharmacy Benefit Strategies for Lowering Prescription Drug Costs Pharmacy Benefit Strategies for Lowering Prescription Drug Costs Mid-sized Retirement and Healthcare Plan Management Conference Chicago, IL June 6, 2012 Pharmacy Benefit Strategies for Lowering Prescription

More information

2017 EMPLOYER SERIES. 6 Things Employers Need to Know About Rising Health Care Costs. Cost Management Key Findings

2017 EMPLOYER SERIES. 6 Things Employers Need to Know About Rising Health Care Costs. Cost Management Key Findings 2017 EMPLOYER SERIES 6 Things Employers Need to Know About Rising Health Care Costs Cost Management 2017 Key Findings It s one of the biggest challenges employers face today: keeping health care costs

More information

34 th Annual J.P. Morgan Healthcare Conference. Steve Collis, President & CEO Tim Guttman, EVP & CFO

34 th Annual J.P. Morgan Healthcare Conference. Steve Collis, President & CEO Tim Guttman, EVP & CFO 34 th Annual J.P. Morgan Healthcare Conference Steve Collis, President & CEO Tim Guttman, EVP & CFO January 12, 2016 Steve Collis President & CEO Cautionary Note Regarding Forward-Looking Statements Certain

More information

Investor Conference. Health Net Pharmaceutical Services

Investor Conference. Health Net Pharmaceutical Services Investor Conference Health Net Pharmaceutical Services John Sivori President, Health Net Pharmaceutical Services December 13, 2006 Health Net Pharmaceutical Services: What We Do HNPS (HNT s PBM) manages

More information

Welcome. AMCP Partnership Forum. Designing Benefits and Payment Models for Innovative High Investment Medications

Welcome. AMCP Partnership Forum. Designing Benefits and Payment Models for Innovative High Investment Medications AMCP Partnership Forum Designing Benefits and Payment Models for Innovative High Investment Medications Welcome Bri Palowitch, PharmD, BCGP Manager, Pharmacy Affairs Academy of Managed Care Pharmacy Disclaimer

More information

UnitedHealth Group Fourth Quarter and Year End 2014 Results Teleconference Prepared Remarks January 21, Moderator:

UnitedHealth Group Fourth Quarter and Year End 2014 Results Teleconference Prepared Remarks January 21, Moderator: UnitedHealth Group Fourth Quarter and Year End 2014 Results Teleconference Prepared Remarks January 21, 2015 Moderator: Good morning, I will be your conference facilitator today. Welcome to the UnitedHealth

More information

eprescribing s Formulary and Benefits: At a Crossroad By Tony Schueth, Editor-in-Chief

eprescribing s Formulary and Benefits: At a Crossroad By Tony Schueth, Editor-in-Chief eformulary eprescribing s Formulary and Benefits: At a Crossroad By Tony Schueth, Editor-in-Chief Studies have shown that much of the value proposition for eprescribing lies in providing formulary & benefits

More information

PRESCRIPTION DRUG SPENDING IN THE U.S. HEALTH CARE SYSTEM: AN ACTUARIAL PERSPECTIVE

PRESCRIPTION DRUG SPENDING IN THE U.S. HEALTH CARE SYSTEM: AN ACTUARIAL PERSPECTIVE PRESCRIPTION DRUG SPENDING IN THE U.S. HEALTH CARE SYSTEM: AN ACTUARIAL PERSPECTIVE Moderator Audrey Halvorson, Vice Chairperson, Health Practice Council Presenters Karen Bender, Member, Prescription Drug

More information

Co-pay Card Program Monitoring and Optimization November 2014

Co-pay Card Program Monitoring and Optimization November 2014 Primary/Final Payer Analysis Co-pay Card Program Monitoring and Optimization November 2014 Symphony Health Solutions offers an array of Managed Markets Studies CONSULTING/ANALYTICAL STUDIES Managed Markets

More information

Delivering Value for All Health Care Stakeholders. Larry Merlo President & Chief Executive Officer

Delivering Value for All Health Care Stakeholders. Larry Merlo President & Chief Executive Officer Delivering Value for All Health Care Stakeholders Larry Merlo President & Chief Executive Officer Agenda Our Value Proposition Has Never Been Stronger We See Compelling Opportunities in a Robust Health

More information

Diplomat s Acquisition of LDI Integrated Pharmacy Services. Nov. 15, 2017

Diplomat s Acquisition of LDI Integrated Pharmacy Services. Nov. 15, 2017 Diplomat s Acquisition of LDI Integrated Pharmacy Services Nov. 15, 2017 1 DISCLAIMERS NON-GAAP INFORMATION We define Adjusted EBITDA as net income (loss) before interest expense, income taxes, depreciation

More information

How the Blueprint Policy Statement to Lower Drug Costs and Reduce Out-of- Pocket Costs May Affect Employers

How the Blueprint Policy Statement to Lower Drug Costs and Reduce Out-of- Pocket Costs May Affect Employers How the Blueprint Policy Statement to Lower Drug Costs and Reduce Out-of- Pocket Costs May Affect Employers Presented by: Lorie Maring Phone: (404) 240-4225 Email: lmaring@ AGENDA Provide an overview of

More information

Cost Sharing Cuts Employers' Drug Spending but Employees Don't Get the Savings

Cost Sharing Cuts Employers' Drug Spending but Employees Don't Get the Savings Cost Sharing Cuts Employers' Drug Spending but Employees Don't Get the Savings Putting the brakes on drug costs Spending on outpatient prescription drugs has increased at double-digit rates for the past

More information

March 4, Dear Senator Wyden and Senator Grassley,

March 4, Dear Senator Wyden and Senator Grassley, March 4, 2016 The Honorable Ron Wyden Ranking Member Committee on Finance United States Senate The Honorable Charles Grassley Member Committee on Finance United States Senate Dear Senator Wyden and Senator

More information

SPECIALTY DRUGS on the Self-Insured Employer: The Current and Future Challenge & What You Can Do

SPECIALTY DRUGS on the Self-Insured Employer: The Current and Future Challenge & What You Can Do The Impact of SPECIALTY DRUGS on the Self-Insured Employer: The Current and Future Challenge & What You Can Do by Kjel Johnson, PharmD, BCPS, FCCP, FAMCP; Senior Vice President of Strategy and Business

More information

ACTIVELY MANAGED DRUG SOLUTIONS ADVISOR. for maintenance and specialty medication. Product Guide

ACTIVELY MANAGED DRUG SOLUTIONS ADVISOR. for maintenance and specialty medication. Product Guide ADVISOR ACTIVELY MANAGED DRUG SOLUTIONS for maintenance and specialty medication Product Guide Actively Managed Drug Solutions is not available in the province of Quebec WHAT S THE PROBLEM? Chronic disease

More information

RISK SHARE AGREEMENTS

RISK SHARE AGREEMENTS THIRD PLENARY: Risk Sharing Agreements: Country Experiences, Challenges, and Lessons Learned Gergana Zlateva Pfizer Inc New York, NY, USA RISK SHARE AGREEMENTS Gergana Zlateva, PhD VP, Global Market Access

More information

November 2017 Follow the Dollar

November 2017 Follow the Dollar November 2017 Follow the Dollar Understanding How the Pharmaceutical Distribution and Payment System Shapes the Prices of Brand Medicines Table of Contents Introduction 1 From the Factory to the Pharmacy

More information

Modeling Price Increases and the Effects on Customer Segments

Modeling Price Increases and the Effects on Customer Segments Modeling Price Increases and the Effects on Customer Segments CBI Medicaid Congress May 9, 2017 Jennifer English Director, Pricing, Contracting and Govt Programs, Insmed, Inc. Disclaimer The opinions and

More information